Abbott Laboratories ABT

101.29 0.22 0.22% as of 25 Sep
Market cap
$174.8B
P/E
32.8×
Indexes indicate stock being part of an index,
Growth Flags show if company had growth for consecutive years,
Insider Buys alert about insiders buying in the last 12 month

Abbott Laboratories (ABT) Revenue growth

Abbott Laboratories's revenue growth over the twelve months to 30 June 2026 was 8.06%, up 2.4 percentage points from fiscal 2025 (5.67%). Over the past ten years it has ranged from −8.12% (fiscal 2023) to 31.4% (fiscal 2017); the current reading is higher than 64% of that period. That is below the Medical Devices industry median of 8.80% and in line with the Healthcare sector median of 8.26%.

Revenue growth, annual

Annual

Period Revenue growth Change (points)
FY2025 5.67% 1.08
FY2024 4.59% 12.71
FY2023 −8.12% (9.46)
FY2022 1.34% (23.13)
FY2021 24.5% 15.99
FY2020 8.48% 4.14
FY2019 4.34% (7.30)
FY2018 11.6% (19.71)
FY2017 31.4% 29.15
FY2016 2.20% 1.42

Quarterly

Period Revenue growth Change (points)
Jun 2026 13.0% 5.24
Mar 2026 7.78% 3.36
Dec 2025 4.42% (2.48)
Sep 2025 6.90% (0.47)
42 more quarters

Against its own ten years

Low −8.12% High 31.4%
Ten-year median 4.59%
Current reading's percentile 64

Revenue growth against peers

Company Revenue growth
DXCM DexCom, Inc. compare 15.5%
EW Edwards Lifesciences Corporation compare 14.6%
BSX Boston Scientific Corporation compare 13.5%
MDT Medtronic PLC compare 9.77%
PHG Koninklijke Philips N.V. compare 9.11%
SYK Stryker Corporation compare 8.48%
STE STERIS plc compare 8.37%
ABT Abbott Laboratories 8.06%
GEHC GE HealthCare Technologies Inc. compare 6.51%
Medical Devices industry median 8.80%
Healthcare sector median 8.26%
Market median 7.41%

What Revenue growth is

Revenue Growth shows how fast a company’s sales are rising or falling compared with the same period a year earlier.

(Revenue − Revenue a year earlier) ÷ |Revenue a year earlier|

The full definition of Revenue growth →

More on ABT